Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Other Events
Item 8.01. Other Events
On April 12, 2017, Protalix BioTherapeutics, Inc. (the Company)
issued a press release announcing positive results from the
Companys phase II clinical trial of alidornase alfa for the
treatment of Cystic Fibrosis. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated by reference
herein.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 | Press release dated April 12, 2017. |
About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company’s product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session down -0.03 at 1.31 with 2,376,097 shares trading hands.